499 related articles for article (PubMed ID: 16556174)
21. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
22. Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery.
O'Riordan JM; Byrne PJ; Ravi N; Keeling PW; Reynolds JV
Am J Surg; 2004 Jul; 188(1):27-33. PubMed ID: 15219481
[TBL] [Abstract][Full Text] [Related]
23. Barrett's oesophagus: the new endoscopic modalities have a future.
Deviere J
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
[TBL] [Abstract][Full Text] [Related]
24. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
Menges M; Müller M; Zeitz M
Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
[TBL] [Abstract][Full Text] [Related]
25. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up.
Ackroyd R; Kelty CJ; Brown NJ; Stephenson TJ; Stoddard CJ; Reed MW
Endoscopy; 2003 Jun; 35(6):496-501. PubMed ID: 12783347
[TBL] [Abstract][Full Text] [Related]
26. High-grade dysplasia in Barrett's oesophagus: natural history and review of clinical practice.
Thomas T; Richards CJ; de Caestecker JS; Robinson RJ
Aliment Pharmacol Ther; 2005 Mar; 21(6):747-55. PubMed ID: 15771761
[TBL] [Abstract][Full Text] [Related]
27. A surveillance programme for Barrett's oesophagus in a UK general hospital.
Olithselvan A; Gorard DA; McIntyre AS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
[TBL] [Abstract][Full Text] [Related]
28. Barrett's oesophagus: results from a 13-year surveillance programme.
Bani-Hani K; Sue-Ling H; Johnston D; Axon AT; Martin IG
Eur J Gastroenterol Hepatol; 2000 Jun; 12(6):649-54. PubMed ID: 10912484
[TBL] [Abstract][Full Text] [Related]
29. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
30. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus.
Fortun PJ; Anagnostopoulos GK; Kaye P; James M; Foley S; Samuel S; Shonde A; Badreldin R; Campbell E; Hawkey CJ; Ragunath K
Aliment Pharmacol Ther; 2006 Mar; 23(6):735-42. PubMed ID: 16556175
[TBL] [Abstract][Full Text] [Related]
31. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Gerson LB; Shetler K; Triadafilopoulos G
Dig Liver Dis; 2005 Sep; 37(9):651-8. PubMed ID: 15919250
[TBL] [Abstract][Full Text] [Related]
32. Meta analysis: Cancer risk in Barrett's oesophagus.
Thomas T; Abrams KR; De Caestecker JS; Robinson RJ
Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1465-77. PubMed ID: 17900269
[TBL] [Abstract][Full Text] [Related]
33. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
[TBL] [Abstract][Full Text] [Related]
34. Incidence of colorectal cancer in a population-based cohort of patients with Barrett's oesophagus.
Murphy SJ; Anderson LA; Mainie I; Fitzpatrick DA; Johnston BT; Watson RG; Gavin AT; Murray LJ
Scand J Gastroenterol; 2005 Dec; 40(12):1449-53. PubMed ID: 16316894
[TBL] [Abstract][Full Text] [Related]
35. Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus.
Sampliner RE; Camargo L; Fass R
Am J Gastroenterol; 2002 Feb; 97(2):270-2. PubMed ID: 11866260
[TBL] [Abstract][Full Text] [Related]
36. The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results.
Zaninotto G; Minnei F; Guirroli E; Ceolin M; Battaglia G; Bellumat A; Betetto G; Bozzola L; Cassaro M; Cataudella G; Dal Bò N; Farinati F; Florea G; Furlanetto A; Galliani E; Germanà B; Guerini A; Macrì E; Marcon V; Mastropaolo G; Meggio A; Miori G; Morelli L; Murer B; Norberto L; Togni R; Valiante F; Rugge M
Dig Liver Dis; 2007 Jan; 39(1):18-25. PubMed ID: 17141593
[TBL] [Abstract][Full Text] [Related]
37. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis.
Corey KE; Schmitz SM; Shaheen NJ
Am J Gastroenterol; 2003 Nov; 98(11):2390-4. PubMed ID: 14638338
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of Barrett esophagus with argon plasma coagulation with acid suppression--a prospective study].
Martin WR; Jakobs R; Spiethoff A; Maass S; Riemann JF
Z Gastroenterol; 1999 Sep; 37(9):779-84. PubMed ID: 10522363
[TBL] [Abstract][Full Text] [Related]
39. Gastroesophageal reflux disease and Barrett's esophagus.
Falk GW
Endoscopy; 2001 Feb; 33(2):109-18. PubMed ID: 11272213
[TBL] [Abstract][Full Text] [Related]
40. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3420-6. PubMed ID: 10606297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
